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Abstract
A recent large-scale meta-analysis of genome-wide studies has identified 95 loci, 59 of them novel, as statistically significant
predictors of blood lipid traits; we tested whether the same loci explain the observed heterogeneity in response to lipid-
lowering therapy with fenofibrate. Using data from the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN,
n = 861) we fit linear mixed models with the genetic markers as predictors and high-density lipoprotein (HDL) cholesterol,
low-density lipoprotein (LDL) cholesterol, total cholesterol, and triglyceride concentrations as outcomes. For all four traits,
we analyzed both baseline levels and changes in response to treatment with fenofibrate. For the markers that were
significantly associated with fenofibrate response, we fit additional models evaluating potential epistatic interactions. All
models were adjusted for age, sex, and study center as fixed effects, and pedigree as a random effect. Statistically significant
associations were observed between the rs964184 polymorphism near APOA1 (P-value#0.0001) and fenofibrate response
for HDL and triglycerides. The association was replicated in the Pharmacogenetics of Hypertriglyceridemia in Hispanics
study (HyperTG, n = 267). Suggestive associations with fenofibrate response were observed for markers in or near PDE3A,
MOSC1, FLJ36070, CETP, the APOE-APOC1-APOC4-APOC2, and CILP2. Finally, we present strong evidence for epistasis (P-value
for interaction = 0.0006 in GOLDN, 0.05 in HyperTG) between rs10401969 near CILP2 and rs4420638 in the APOE-APOC1-
APOC4-APOC2 cluster with total cholesterol response to fenofibrate. In conclusion, we present evidence linking several novel
and biologically relevant genetic polymorphisms to lipid lowering drug response, as well as suggesting novel gene-gene
interactions in fenofibrate pharmacogenetics.
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Introduction
A recent large-scale meta-analysis of genome-wide studies has
identified 95 loci, 59 of them novel, to be significantly associated
with fasting blood lipid traits, including high density lipoprotein
(HDL) cholesterol, low density lipoprotein (LDL) cholesterol, total
cholesterol, and triglycerides. Together these variants explain 10–
12% of phenotypic variability [1,2]. However, it remains unknown
whether genetic variation at these loci also mediates the effects of
lipid-lowering pharmaceutical agents.
One such agent is fenofibrate, a peroxisome proliferator-
activated receptor-a (PPAR-a) agonist that is widely used to treat
dyslipidemia. Individual response to fenofibrate therapy is highly
heterogeneous, suggesting a role for pharmacogenetic predictors
[3,4]. Although prior studies have implicated single nucleotide
polymorphisms (SNPs) in genes such as CYP7A1, PPARA, and the
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APOA1/C3/A4/A5 cluster in lipid response to fenofibrate, their
findings explain only a small percentage of outcome variation [5–
7]. Similarly to other complex traits, the effect of fenofibrate
treatment on lipids is likely to have a non-linear genetic
architecture, as evidence suggests that triglyceride response in
particular is influenced by epistatic interactions in a subset of key
polymorphisms [8]. However, reports on changes in other lipid
outcomes remain limited to single gene analyses, prompting a
comprehensive approach to discovering novel biologically relevant
loci. If successfully validated, newly discovered markers could be
used as predictive tools to guide clinical treatment decisions [9].
This study investigated whether the previously validated genetic
predictors of lipid traits are associated with baseline blood lipids as
well as with the change in triglycerides, HDL-, LDL-, and total
cholesterol following 3 weeks of fenofibrate therapy in the
participants of the Genetics of Lipid Lowering Drugs and Diet
Network (GOLDN). For those genetic markers that produced
statistically significant associations with the change in lipids, we
conducted replication analyses in a cohort of Mexican-Americans
treated with fenofibrate: the Pharmacogenetics of Hypertriglycer-
idemia in Hispanics study (HyperTG, n= 267). Additionally, for
the top fenofibrate-related markers, we evaluated all possible
pairwise epistatic combinations and tested the statistically signif-
icant interactions in the HyperTG population, providing further
insights into the biology of lipid response to fenofibrate.
Results
Of the 95 loci originally validated as blood lipid concentration
predictors, 6 were not associated with the outcomes in Caucasian
populations and thus excluded from subsequent analyses, as the
GOLDN cohort is entirely comprised of European Americans
(Table S1). Additionally, genotype information for the rs9411489
marker in the ABO gene was not available in GOLDN, so we
identified and used rs495828 as its proxy (r2 = 1.00, D’ = 1.00 in
the CEU subpopulation of 1000 Genomes). The remaining SNPs
were either genotyped or imputed with a high degree of accuracy;
out of the 80 imputed SNPs, none had an imputation quality score
(R-squared) below 0.3 and only 11 had an imputation quality score
below 0.8. Additionally, no evidence of deviation from Hardy-
Weinberg equilibrium (P,161026) was found for any of the 15
genotyped loci. Finally, none of the examined SNPs were rare
(minor allele frequency (MAF) ,0.01) in the GOLDN study
population (Table S1).
Clinical and demographic characteristics of the GOLDN and
HyperTG populations are shown in Table 1. Except for the
ethnicity distinction, the discovery and replication cohorts had
similar demographic and risk factor profiles. In both cohorts,
participants were middle-aged (48616 years in GOLDN, 41612
in HyperTG) and evenly split between genders. The mean LDL-
and total cholesterol concentrations at baseline were below
national averages, suggesting a favorable lipoprotein profile in
the study population, although the observed serum HDL
cholesterol was also slightly below the national average [10].
Following the three-week treatment with fenofibrate, clinically
significant changes were observed for all four lipid outcomes
(Table 1).
The top genetic predictors of lipid fenofibrate response are listed
in Table 2, with SNPs that were tested but not found to be
significant pharmacogenetic predictors summarized in Table S2.
The threshold for Bonferroni correction for multiple comparisons
was based on 356 tests (86 SNPs x 4 lipid outcomes), which yields
an adjusted alpha level of 0.0001. The strongest association in
GOLDN, which replicated successfully in HyperTG, was observed
between the rs964184 polymorphism near APOA1 and increased
HDL cholesterol and triglycerides following fenofibrate therapy.
Additionally, in GOLDN it reached suggestive significance levels
for changes in LDL cholesterol, although the magnitude of the
corresponding associations was more modest for fenofibrate
response than for baseline values. At baseline, rs964184 was
associated with triglycerides (Table S3). Additionally, rs3764261 in
the CETP gene was found to be associated with HDL cholesterol
at baseline in GOLDN (Table S3). Overall, the top associated
SNPs for each lipoprotein type varied between baseline and
response values in either genomic region, magnitude of association
(as indicated by a range of F-statistics), or both, suggesting a
decreased likelihood of bias due to residual confounding by
baseline lipid concentration.
Table 3 and Figur S1 summarize the evidence for epistatic
interaction for selected genes in GOLDN and HyperTG. Based on
a Bonferroni-adjusted alpha level of 0.003 resulting from
simultaneously testing 17 pairwise interaction hypotheses, statis-
tically significant epistasis was observed between rs10401969 near
CILP2 and rs4420638 near APOE for the total cholesterol
outcome. In GOLDN, all cell counts were all greater than 5
participants. However, in the HyperTG cohort, the small sample
size resulted in sparse cells; as a result, we have grouped together
homozygous mutant and heterozygous genotypes for the replica-
tion analysis. In GOLDN, among participants carrying no variant
alleles at the CILP2 locus, the total cholesterol response was slightly
attenuated with each copy of the variant APOE allele. Among
carriers of the minor CILP2 allele, however, the total cholesterol
response was more pronounced, ranging from the ratio of 0.89 for
wildtype APOE homozygotes to 0.83 for carriers of at least one
copy of the variant allele. Although the regression coefficient for
the APOE/CILP2 interaction term also achieved borderline
statistical significance in the replication cohort, it is noteworthy
that the direction of association between CILP2 genotypes and the
Table 1. Clinical and demographic characteristics of the
discovery and replication study populations.
Variable (mean/median*
± SD or %) GOLDN HyperTG
N=861 N=267
Age, years 48616 41612
Sex, % female 50 52
Current smoker, % 8 –
Body mass index, kg/m2 2866 3164
High density lipoprotein cholesterol, mg/dL
Baseline 46.65613.10 41.8369.39
After fenofibrate treatment 49.47613.41 46.35610.51
Low density lipoprotein cholesterol, mg/dL
Baseline 123.18631.47 102.25633.10
After fenofibrate treatment 104.30631.30 89.10628.90
Total cholesterol, mg/dL
Baseline 192.09639.24 186.17637.38
After fenofibrate treatment 166.83634.37 166.27634.38
Triglycerides, mg/dL
Baseline 115.00698.97 198.306136.69
After fenofibrate treatment 75.50655.22 122.956140.68
*Medians were reported for triglycerides only due to skewness in the data.
doi:10.1371/journal.pone.0048663.t001
Genetic Predictors of Lipid Fenofibrate Response
PLOS ONE | www.plosone.org 2 October 2012 | Volume 7 | Issue 10 | e48663
total cholesterol ratio for carriers of at least one copy of the APOE
variant allele was reversed in HyperTG (Figure S1).
Similar interactions were observed between rs10401969 and
rs4420638 for the LDL cholesterol response outcome, consistent
with the high correlation between the two phenotypes. Addition-
ally, there was evidence of suggestive interactions between
rs3764261 in CETP gene rs964184 near APOA1 for LDL
cholesterol. Pairwise interactions between other SNPs listed in
Table 3 were tested but did not approach statistical significance.
Both main effects and gene-gene interaction results were robust to
sensitivity analyses, in which the fenofibrate response outcome was
modeled as the difference between post-treatment and baseline
lipid concentrations, adjusted for the baseline value (data not
shown).
Discussion
In this study, we evaluated whether genetic loci with replicated
associations with circulating blood lipids could also be used as
markers of lipid response to fenofibrate therapy. In addition to
replicating several of the reported gene-phenotype associations in
our study population at baseline, we also present evidence
suggesting that several polymorphisms, most notably in the CETP
and the APOA1 genes, are associated with treatment-related
changes in lipoproteins and triglycerides. Finally, we present data
in support of interactions between variants in APOE and CILP2 in
total cholesterol models concentrations.
The rs964184 locus near the APOA1 gene emerged as the most
consistent predictor of lipid fenofibrate response, showing statis-
tically significant associations for changes in HDL cholesterol and
triglycerides, and approaching statistical significance for LDL
cholesterol. The HDL result replicates findings from a recent
analysis of genetic predictors of response to fenofibrate and statins
among individuals with atherogenic dyslipidemia, which implicat-
ed the rs964184 minor allele in lipid profile improvements
following combination therapy [11]. However, the association
between rs964184 and triglycerides was only observed before
treatment, while in GOLDN data it was associated with both
baseline concentration and fenofibrate response. This discrepancy
could be explained by differences in baseline characteristics
between study populations, as evidenced by better metabolic
health of the GOLDN participants, and/or differences in
treatment regimen. The baseline association with triglycerides
seen in GOLDN was also replicated among dyslipidemic
individuals of Mexican descent, a population in which the
evidence for association is especially strong (odds ratio for
hypertriglyceridemia = 1.74) and the MAF at the rs964184 locus
exceeds that in Caucasians by more than twofold, thus accounting
for a large degree of outcome variability [12].
In the response models, associations approaching statistical
significance were also observed for rs7134375 in the PDE3A gene
and HDL cholesterol; rs2642442 in MOSC1 for LDL cholesterol;
rs492602 in FLJ36070 for total cholesterol; and rs3764261 in
CETP, rs4420638 near the APOE-APOC1-APOC4-APOC2 cluster,
and rs10401969 near CILP2 for both LDL- and total cholesterol.
The observed association with the CETP variant, is concordant
with the extensive evidence demonstrating that fenofibrate
improves lipid profile by reducing cholesteryl ester transfer, a
process dependent on the product of CETP, from HDL to very low
density lipoprotein (VLDL) in both mice [13] and humans [14].
Although a previous study from our group investigated APOE e2/
e3/e4 genotypes as a potential predictor of triglyceride response to
fenofibrate and found no associations [15], the rs492602
polymorphism examined in our analysis represents a distinct
genetic variant within the APOE-APOC1-APOC4-APOC2 cluster
and a novel locus for fenofibrate response. Similarly, SNPs in
PDE3A, MOSC1, CILP2, and FLJ36070 have not been previously
linked to pharmacological changes in lipids and warrant further
investigations in independent populations.
The strongest evidence for epistasis was observed between
rs10401969 near CILP2 and rs4420638 near the APOE-APOC1-
APOC4-APOC2 cluster for both LDL- and total cholesterol. The
two unlinked variants are located on the opposing arms of
chromosome 19. To the best of our knowledge, our study is the
Table 2. Genetic polymorphisms associated with lipid response to fenofibrate therapy in GOLDN (n = 861) and HyperTG (n = 267).
SNP (Variant Allele) Locus F Discovery P-value Replication P-value
Direction of Association Discovery/
Replication
High-density lipoprotein cholesterol
rs964184 (G) APOA1 19.8 ,0.0001 0.04 Increase/Increase
rs7134375 (A) PDE3A 9.3 0.002 0.75 Increase/NS
Low-density lipoprotein cholesterol
rs3764261 (A) CETP 12.9 0.0004 0.38 Decrease/NS
rs4420638 (G) APOE 10.4 0.001 0.10 Increase/NS
rs964184 (G) APOA1 10.1 0.002 0.42 Increase/NS
rs2642442 (C) MOSC1 4.8 0.03 0.25 Decrease/NS
rs10401969 (C) CILP2 4.1 0.04 0.64 Decrease/NS
Total cholesterol
rs3764261 (A) CETP 7.3 0.007 0.19 Decrease/NS
rs4420638 (G) APOE 6.9 0.009 0.18 Increase/NS
rs492602 (G) FLJ36070 6.1 0.01 0.41 Decrease/NS
rs10401969 (C) CILP2 4.9 0.03 0.99 Decrease/NS
Triglycerides
rs964184 (G) APOA1 15.3 0.0001 0.05 Increase/Increase
doi:10.1371/journal.pone.0048663.t002
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first to evaluate their interaction, as the relevance of CILP2 to lipid
metabolism has only recently been established [16]. However, the
observed statistical interaction is biologically plausible, as APOE
variants have previously been shown to interact with other lipid-
related genes to influence therapeutic response [17]. Suggestive
epistasis was also observed between rs3764261 in CETP and the
rs964184 locus near APOA1 in the LDL cholesterol models, which
did not reach statistical significance but is likely to have functional
relevance. Specifically, prior experiments conducted in mice
showed that CETP expression reversed the HDL cholesterol
lowering action of a pregnane X receptor agonist, which was
shown to occur through decreased expression of the APOA1
homolog [18]. Future replication studies, as well as experiments
using CETP knockout animals treated with fenofibrate, could
support the validity of our findings and further elucidate the
epistatic mechanisms underlying response to lipid-lowering drugs.
The results of our study should be interpreted in the context of
several important considerations. First, only a subset of our
findings were evaluated and replicated in an independent
population. Reasons for such partial non-replication are manifold
and could include effect modification by ancestry or other baseline
factors, lack of statistical power in the smaller replication cohort,
variation in fenofibrate regimen (3 weeks vs. 8 weeks) and
compliance, and others. In light of these concerns, we have taken
great care to reduce the likelihood of false positive findings, namely
by using extremely conservative multiple testing adjustments and
presenting evidence of biological relevance of the examined loci.
Additionally, stringent genotyping quality control procedures
implemented in GOLDN, high imputation quality scores
(Table S1), and the absence of implausibly low P-values all serve
to indirectly corroborate the validity of our findings [19].
Second, we chose a candidate gene approach rather than
conduct a genome-wide association study to enable biologically
informed analyses of gene-gene interactions and single marker
associations. Given that effect of any given genetic marker on a
complex trait like fenofibrate response is likely to be small, the
sample size of both discovery and replication cohorts would have
been insufficient to conduct a genome-wide search for interactions,
or possibly even to reveal all relevant single markers. Therefore,
we have built our research question upon a priori understanding of
fenofibrate pharmacogenetics as well as robust evidence of genetic
determinants of lipid levels published by Teslovich et al. [1]. For
similar reasons, we did not evaluate any higher-order interactions,
which could potentially contribute to the genetic architecture of
the outcome and either mask or alter the effects of the examined
genetic variants [20].
Third, the loci identified in the original meta-analysis represent
only common variants, even though recent evidence highlights the
importance of rare variants in the genetic architecture of lipid
traits [21]. Fourth, the baseline lipid profile of our discovery
population is more favorable than in those with true indication for
fenofibrate, limiting the generalizability of our findings. Finally,
the current study can offer only limited mechanistic insights into
the relationship between rs964184 near APOA1 and the lipid
response to fenofibrate. Future studies may consider investigating
the association between variation at that locus and fenofibrate-
Table 3. Suggestive evidence of gene-gene interactions for selected serum lipid concentrations and genotypes.
Joint Genotype MA1*6MA2
Post-Treatment to Baseline
Ratio ± SE (Discovery)
Interaction P-value
(Discovery)
Interaction P-value
(Replication)
Total cholesterol
rs10401969 and rs4420638 0 0.8660.007 0.0006** 0.05
1 0.9360.04
2 0.9960.04
4 1.0160.10
Low density lipoprotein cholesterol
rs964184 and rs3764261 0 0.7960.03 0.004 0.61
1 0.8160.02
2 0.9060.02
4 1.0060.06
rs964184 and rs4420638 0 0.6960.08 0.02 0.77
1 0.7160.06
2 0.8160.02
4 0.9360.13
rs10401969 and rs4420638 0 0.8460.01 0.04 NA
1 0.9160.07
2 0.9860.07
4 0.8960.18
rs964184 and rs2642442 0 0.8160.02 0.07 0.14
1 0.8660.02
2 0.8960.02
4 0.9660.06
*Minor allele count.
**Survives Bonferroni correction for 17 hypotheses.
doi:10.1371/journal.pone.0048663.t003
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induced changes in plasma apolipoproteins (specifically apoA-I,
apoC-III, apoA-IV, or apoA-V) to elucidate the underlying
biological pathways.
In conclusion, we have successfully confirmed associations
between key loci and circulating lipids in baseline as well as
identified novel genetic predictors of lipid response to fenofibrate.
We also found biologically relevant interactions between polymor-
phisms near CILP2 and the APOE-APOC1-APOC4-APOC2 cluster in
the LDL- and total cholesterol models, adding to the body of
evidence suggesting that genetic factors have an important and
nuanced role in determining effectiveness of lipid-lowering therapy.
Materials and Methods
Ethics Statement
Participants provided written informed consent and all research
was conducted according to the principles outlined in the
Declaration of Helsinki. The protocol was approved by the
Institutional Review Boards at the University of Minnesota,
University of Utah, Tufts University/New England Medical
Center, UCLA, Cedars-Sinai Medical Center, and the University
of Alabama at Birmingham.
Discovery Study Population
Detailed descriptions of methods, including genotyping and
circulating lipids measurement, are presented in Text S1. Briefly,
the National Heart, Lung, and Blood Institute GOLDN study,
described in detail in previous publications [13,22], was designed
to identify genetic determinants of lipid response to daily treatment
with 160 mg of micronized fenofibrate over the course of three
weeks. GOLDN recruited European American pedigrees with at
least two siblings from the genetically homogeneous communities
of Minneapolis, MN, and Salt Lake City, UT. For the fenofibrate
portion of the trial, participants discontinued the use of lipid-
lowering agents for at least 4 weeks, fasted for at least 8 hours
prior to study visits, and abstained from alcohol for at least
24 hours before each study visit. Circulating blood lipids were
measured at baseline and following the three-week treatment
period. A total of 906,600 SNPs were genotyped using the
Affymetrix Genome-Wide Human 6.0 array and the Birdseed
calling algorithm [23]. After quality control exclusions, 584,029
typed SNPs remained. We subsequently imputed untyped SNPs
using Human Genome Build 36 as referent, and created a hybrid
dataset that included a total of 2,543,887 SNPs (584,029 typed and
1,959,858 imputed) [23]. Population stratification was assessed
using principal component analysis and found to be limited in our
study population [23].
Participants were excluded from the analysis if they if they were
missing outcome data, yielding n= 861 for the single marker
analyses. Of those, participants that were missing genotype
information at specific loci were excluded from the respective
analyses, which explains the reduced sample size in the epistasis
models. Outcomes were defined as: 1) baseline treatment plasma
concentrations ofHDL-, LDL-, total cholesterol and triglycerides; 2)
post-treatment/baseline ratios of plasma concentrations for the four
outcomes as defined above. Log- transformations were carried out
for triglyceride ratios as the variable was not normally distributed.
Sensitivity analyses were conducted defining the outcome as the
difference in post- and pre-fenofibrate treatment lipid concentra-
tions with the model adjusted for baseline concentrations, as well as
with using non-HDL cholesterol as an outcome.
Linear mixed models were fit to evaluate the associations
between single markers previously linked to lipid levels in
European individuals [1] and the outcomes, adjusted for sex,
age, and center as fixed effects, and pedigree as a random effect.
The additive assumption was used to model genotypes. The SNPs
that showed a suggestive or statistically significant association with
the outcomes (nominal P-value ,0.05) were included in subse-
quent interaction analyses, in which a multiplicative term between
any two given SNPs was included into the regression model as
described above. For the single marker analyses, P-values were
adjusted for multiple testing using the Bonferroni approach based
on 356 hypotheses (86 SNPs x 4 lipid outcomes), with the final
adjusted alpha level of 0.0001. For the interaction analyses, the
Bonferroni correction was based on the 17 pairwise tests, yielding
a statistical significance threshold of 0.003. The chosen corrections
are likely to be conservative given the highly correlated nature of
the lipid phenotypes. All association analyses were carried out in
SAS v. 9.2 (Cary, NC).
Replication Study Population
HyperTG recruited 350 Hispanic-American participants from
Los Angeles, CA for a pharmacogenetic study of the response to
fenofibrate (160 mg per day for 8 weeks). Of the 350 subjects, 267
had complete total cholesterol, HDL cholesterol, and triglyceride
measurements and genotype data and were analyzed in this study
for the replication of the 7 SNP associations. Pedigree structure
was examined and potential population stratification was assessed
using principal component analysis.
Outcomes were defined as: 1) baseline treatment plasma
concentrations of HDL-, LDL-, total cholesterol and triglycerides;
2) post-treatment/baseline ratios of plasma concentrations for the
four outcomes as defined above. Participants were excluded from
the LDL cholesterol analysis if their triglyceride value was larger
than 400 mg/dL. Log- transformations were carried out for
baseline triglyceride levels and the four treatment/baseline ratios
because the raw data were not normally distributed. Sensitivity
analyses were conducted defining the outcome as the difference in
post- and pre-fenofibrate treatment lipid concentrations with the
model adjusting for and baseline concentrations, as well as with
using non-HDL cholesterol as an outcome.
Linear mixed models were fit to evaluate the associations
between each of the 7 single SNPs identified in GOLDN and the
outcomes, adjusted for sex, age, and pedigree as a random effect.
The additive assumption was used to model genotypes. In the
replication of the interaction analyses of the four pairs of markers
rs964184*rs3764261, rs964184*rs4420638, rs964184*rs2642442
and rs10401969*rs4420638, a multiplicative term between the two
SNPs was included into the regression model. All association
analyses were carried out in SAS v. 9.2 (Cary, NC).
Supporting Information
Figure S1 Evidence of epistatic interaction between
rs10401969 and rs4420638 in total cholesterol response
to fenofibrate in (A) the discovery GOLDN cohort
(n= 861) and (B) replication HyperTG cohort (n=267).
(DOCX)
Table S1 Characteristics of loci identified by Teslovich
et al. to be associated with plasma lipids in the GOLDN
population.
(DOC)
Table S2 Genetic polymorphisms identified by Teslo-
vich et al. that were not found to be associated with lipid
response to fenofibrate therapy in GOLDN (n=861).
(DOC)
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Table S3 Associations between selected genetic poly-
morphisms and lipid concentrations at baseline.
(DOC)
Text S1 Detailed description of genotyping and circu-
lating blood lipid measurement in the GOLDN and
HyperTG studies.
(DOC)
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